ClinicalTrials.gg
Enrolling by invitationNCT07422831T2D INSIGHTUpdated Apr 29, 2026

T2D Intermittent Nonprescription Sensors for Informed Glucose Health Tracking

An interventional study of Periodic, over-the-counter continuous glucose monitoring in Type 2 Diabetes and Non Insulin Dependent Diabetes, sponsored by University of Colorado, Denver. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.

Sponsored by University of Colorado, Denver · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver — 6 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 2 · University of Colorado, Denver.

Planned enrollment
8th of 33
188 · median 62
Started
2026
with 2 others
No phase
26 of 41
5 open now
Registered
41st of 41
by date

Among the 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver, this one is the 8th largest by planned enrollment of the 33 interventional ones that give a count, is one of 3 that started in 2026, is one of 26 with no phase, and was the 41st registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

6 of the 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Diabetes Mellitus, Type 2 by University of Colorado, Denver, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if periodic use of over-the-counter continuous glucose monitoring (CGM) can support glucose management in people with type 2 diabetes not using insulin being treated in primary care settings. The main questions it aims to answer are:

  • Is periodic use of CGM every 30 or 90 days for six months associated with reduced A1C compared to usual care at baseline?
  • Is periodic use of CGM every 30 or 90 days for six months associated with increased time in range and time in tight range compared to usual care at baseline?
  • Is periodic use of CGM every 90 days over six months associated with non-inferior A1C reduction compared to periodic use of CGM every 30 days?
  • Are clinician feasibility and acceptability of periodic, OTC CGM higher than for prescription CGM?
  • How acceptable is periodic, OTC CGM to people with non-insulin-treated type 2 diabetes? Researchers will compare use of periodic CGM every 30 and 90 days to see if less frequent periodic CGM use can support glucose management as effectively as more frequent use.

Participants will:

  • be assigned to one of two groups using the 15-day Dexcom Stelo® glucose biosensor every 30 or 90 days over a six-month period.
  • receive Stelo devices every 30 or 90 days (as randomized)
  • complete up to 9 virtual or in-person visits with the study team.
  • complete 3 fingerstick A1c tests.
  • wear a blinded CGM device at 3 time points outside of Dexcom Stelo® use.
  • complete a survey at the end of the study.
03

Conditions studied

  • Type 2 Diabetes
  • Non Insulin Dependent Diabetes

Keywords

  • Continuous glucose monitoring
  • Primary care
  • Diabetes management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years at time of enrollment
  2. Diagnosis of type 2 diabetes
  3. Able to read and understand English (Dexcom Stelo is currently only available in English)
  4. No real-time or intermittently scanned (Flash) CGM use 12 months prior to enrollment
  5. Stable medication regimen (medication classes) and dose (equivalent dose if medication has been changed within the same medication class) for any glucose lowering or weight loss medications for 30 days prior to enrollment and willing to not change medications prior to randomization unless safety concerns.
  6. Cell phone meeting minimum required OS compatibility with Stelo
  7. Willing to use the study device and download the Stelo app
  8. Willing and able to complete all study procedures per investigator discretion, including willingness to accept either experimental group (q30 or q90).
  9. value (from lab data or chart review) greater than or equal to 6.5 in the 6 months prior to enrollment
  10. Currently receiving primary care in a participating study practice

Exclusion criteria

Exclusion Criteria:

  1. Use of insulin in the 12 months prior to screening or planning to initiate insulin during the next 12 months (short-term use of insulin in an inpatient setting is acceptable)
  2. Concomitant disease or condition that in the opinion of the investigator may compromise patient safety including but not limited to severe mental illness, a diagnosed or suspected eating disorder, or any uncontrolled or chronic medical condition that would interfere with study related tasks or visits
  3. Use within 30 days of screening visit of any medication that in the opinion of the investigator may exacerbate glucose dysfunction (e.g. systemic )
  4. Current or planned use of hydroxyurea (due to interference with CGM)
  5. Known presence of a hemoglobinopathy or other condition that is expected to affect the measurement of in the judgment of the investigator
  6. Known severe allergy to medical grade adhesive, a serious skin condition that could interfere with CGM placement, or extensive tattoos that precludes the use of CGM in an FDA approved location
  7. End stage renal disease currently managed by dialysis or \<30 mL/min/1.73m2
  8. Current participation in another interventional study protocol that could impact participation in this study per investigator discretion
  9. Pregnant or planning to become pregnant within the next 6 months.
  10. Planning to switch primary care practices in the next 6 months.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
188 participants (estimated)

Study arms

  • Experimental
    30 day

    Use of periodic, OTC CGM every 30 days for six months.

    Device: Periodic, over-the-counter continuous glucose monitoring

  • Experimental
    90 day

    Use of periodic, OTC CGM every 90 days for six months.

    Device: Periodic, over-the-counter continuous glucose monitoring

Interventions

  • DevicePeriodic, over-the-counter continuous glucose monitoring

    Periodic, over-the-counter continuous glucose monitoring for people with non-insulin-treated type 2 diabetes treated in primary care settings.

06

What researchers measure

Primary outcomes

  1. Change in A1C from baseline to 6 months

    Change in A1C from baseline (enrollment) to 6 months.

    Time frame: From enrollment to completion of study visits at 6 months

Secondary outcomes

  1. Change in Time in Range from baseline to 6 months

    Change in time in range (TIR) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.

    Time frame: From enrollment to the completion of study visits at 6 months.

  2. Change in Time in Tight Range from baseline to 6 months

    Change in time in tight range (TITR) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.

    Time frame: From enrollment to the completion of study visits at 6 months.

  3. Change in mean glucose from baseline to 6 months

    Change in mean glucose collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.

    Time frame: From enrollment to the completion of study visits at 6 months.

  4. Change in TAR (>180) from baseline to 6 months

    Change in time above range (\>180 mg/dL) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months.

    Time frame: From enrollment to the completion of study visits at 6 months.

  5. Change in A1C from baseline to 3 months.

    Change in A1C from baseline (enrollment) to 3 months.

    Time frame: From enrollment to 3-month study visit

  6. Change in TIR from baseline to 3 months.

    Change in TIR from baseline (enrollment) to 3 months.

    Time frame: From enrollment to 3-month study visit

  7. Change in TITR from baseline to 3 months.

    Change in TITR from baseline (enrollment) to 3 months.

    Time frame: From enrollment to 3-month study visit

  8. Change in mean glucose from baseline to 3 months

    Change in mean glucose collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to the 3-month study visit.

    Time frame: From enrollment to 3-month study visit

  9. Change in TAR (>180) from baseline to 3 months

    Change in time above range (\>180 mg/dL) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to 3-month study visit.

    Time frame: From enrollment to 3-month study visit

Other outcomes

  1. Feasibility ratings of periodic, OTC CGM to primary care clinicians

    Feasibility of Intervention Measure (FIM) ratings for periodic, over-the-counter continuous glucose monitoring from clinicians in participating practices. FIM items are measured on a Likert scale ranging from (1) Completely disagree to (5) Completely agree. Higher ratings indicate more favorable ratings of intervention feasibility.

    Time frame: Two years following practice study enrollment

  2. Acceptability ratings of periodic, OTC CGM to primary care clinicians

    Acceptability of Intervention Measure (AIM) ratings for periodic, over-the-counter continuous glucose monitoring from clinicians in participating practices. AIM items are measured on a Likert scale ranging from (1) Completely disagree to (5) Completely agree. Higher ratings indicate more favorable ratings of intervention acceptability.

    Time frame: Two years following practice study enrollment

  3. Days of wear of periodic, OTC CGM (Patient Acceptance)

    As a proxy for patient acceptance, we will report mean days of wear for over-the-counter continuous glucose monitoring devices, measured using Dexcom Stelo device metrics. Days of wear range from 0 to 15 days per session. Higher mean values reflect greater levels of patient acceptance.

    Time frame: Two years following practice study enrollment

  4. Glucose monitoring satisfaction for periodic, OTC CGM (Patient Acceptance)

    As a proxy for patient acceptance, we will report patient ratings of satisfaction with periodic, OTC CGM use using the Glucose Monitoring Satisfaction Survey (GMSS). Ratings of GMSS items range from (1) Strongly disagree to (5) Strongly agree, with higher values indicating greater satisfaction.

    Time frame: Two years following practice study enrollment

  5. Willingness to pay for periodic, OTC CGM (Patient Acceptance)

    As a proxy for patient acceptance, we will report patients' willingness to pay for periodic, OTC CGM as measured by percentage of patients willing to pay up to various dollar amounts. Higher willingness-to-pay values and greater percentages of participants willing to pay at various price points reflect greater patient acceptability.

    Time frame: Two years following practice study enrollment

07

Study locations

1 site
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Finalizing data sharing plan for sensitive data sources.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 20 months is close to that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2026
First posted
Feb 20, 2026
StartActual
Apr 2, 2026
Primary completionEst.
Dec 2027
CompletionEst.
Jun 2028
Last update
Apr 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07422831
Collaborators
American Diabetes Association
Responsible party
Sponsor
First posted
Feb 20, 2026
Start date
Apr 2, 2026
Primary completion
Dec 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Apr 29, 2026

Study contacts

Tamara Oser, MD
principal investigator · University of Colorado Denver Anschutz Medical Campus

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion